Highlights of This Issue 107

CELL CYCLE AND SENESCENCE
109  Knockdown of PAK4 or PAK1 Inhibits the Proliferation of Mutant KRAS Colon Cancer Cells Independently of RAF/MEK/ERK and PI3K/AKT Signaling
Hana Tabusa, Teresa Brooks, and Andrew J. Massey

DNA DAMAGE AND REPAIR
161  MYC-Induced Epigenetic Activation of GATA4 in Lung Adenocarcinoma
Inés C. Castro, Achim Breiling, Katharina Luetkenhaus, Fatih Ceteci, Simone Hausmann, Sebastian Kress, Frank Lyko, Thomas Rudel, and Ulf R. Rapp

CELL DEATH AND SURVIVAL
122  Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors
Monica Ceccon, Luca Mologni, William Bisson, Leonardo Scapozza, and Carlo Gambacorti-Passerini

ONCOGENES AND TUMOR SUPPRESSORS
182  miRNA-145 Targets v-ets Erythroblastosis Virus E26 Oncogene Homolog 1 to Suppress the Invasion, Metastasis, and Angiogenesis of Gastric Cancer Cells
Liduan Zheng, Jiarui Pu, Teng Qi, Meng Qi, Dan Li, Xuan Xiang, Kai Huang, and Qiangsong Tong

SIGNAL TRANSDUCTION
194  CLT1 Targets Bladder Cancer through Integrin α5β1 and CLIC3
Lynn M. Knowles, James Zewe, Gunjan Malik, Anil V. Parwani, Jeffrey R. Gingrich, and Jan Pilch

CHROMATIN, GENE, AND RNA REGULATION
149  CPEB1 Regulates the Expression of MTDH/AEG-1 and Glioblastoma Cell Migration
Dawn M. Kochanek and David G. Wells
ABOUT THE COVER

Crizotinib is a selective ALK inhibitor, recently approved for the treatment of ALK+ non-small cell lung cancer and currently in clinical trials for other ALK-related malignancies. By using a human cell-based screening approach, the appearance of two point mutations able to confer crizotinib resistance was observed. One of these mutations is sensitive to two structurally unrelated ALK inhibitors, NVP-TAE 684 and the clinically relevant AP26113, while the second one is resistant to all drugs. For further details, please see Cecon and colleagues on page 122 in this issue.
Molecular Cancer Research

11 (2)


Updated version  Access the most recent version of this article at: http://mcr.aacrjournals.org/content/11/2

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.